Zydus Lifesciences gets USFDA’s tentative approval for Dexamethasone Tablets

09 Feb 2024 Evaluate

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets). Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. 

The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh. Dexamethasone Tablets USP, 1 mg had annual sales of $1.8 million in the United States (IQVIA Dec. Nov. 2023). The group now has 387 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

924.35 -7.10 (-0.76%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×